

Document Title: Assessment and Registration of Trust Risk Rating for Research Studies

Document Number: R&D SOP025

Staff involved in development: <i>Job titles only</i>	Senior R&D Manager, R&D Operational Manager, Clinical Project Managers
Document owner:	Senior R&D Manager
Directorate:	Research and Development
Department:	Research and Development
For use by:	NHS Staff Trust-Wide
Review due:	July 2025
<p><u>THIS IS A CONTROLLED DOCUMENT</u></p> <p>Whilst this document may be printed, the electronic version maintained on the Trust's Intranet is the controlled copy. Any printed copies of this document are not controlled. ©Royal Papworth Hospital NHS Foundation Trust. Not to be reproduced without written permission.</p>	

Summary of Amendments

Version:	Modification:
7.0	Minor administrative changes. Changes in accordance with the Trust Risk Management Strategy

Key Points of this Document

- This document sets out the risk assessment procedure for the calculation of risk that a clinical trial or research study poses and registration of the risk in line with Risk Management Strategy.
- It provides guidance on the procedures to be undertaken to safeguard patients, personnel and the Trust's reputation in light of any risks and hazards identified prior to the commencement of a study.

1 Purpose and Content

- a. This document defines the Trust's procedures in terms of identifying the risks posed by Research Studies and Clinical Trials that will be performed at Royal Papworth Hospital NHS Foundation Trust, and how these risks are registered in accordance with Trust Risk Management Strategy (DN139). It covers Royal Papworth sponsored research as well as externally sponsored research where Royal Papworth acts as a participating site.
- b. The document describes the requirement for performing risk assessments in line with the Trust Risk Strategy
- c. The document aims to provide clear guidance on performing the risk assessment of studies as part of the Trust Confirmation of Capacity and Capability (TCCC) process and subsequent actions.
- d. The monitoring of a study or trial to ensure it is being conducted in accordance with the approved study protocol is outside the scope of this SOP and is described in [SOP016: Monitoring Research Studies](#) and [SOP085 Monitoring Research Studies - External Monitors and Remote Monitoring.pdf](#).
- e. The TCCC process is outside the scope of this SOP and is described in [SOP034: Trust Confirmation of Capacity and Capability to Conduct Research Studies](#).
- f. In addition to the risk assessment outlined below, all clinical trials of investigational medicinal products (CTIMPs) but undergo an additional risk review as detailed in SOP065: Risk-adapted Approach to the Management of Clinical Trials of Investigational Medicinal Products

2 Roles & Responsibilities

- a. This Policy applies to all personnel that are conducting research at the Trust.
- b. Staff involved in the design and set-up of research studies and clinical trials must comply with the requirements set out in section 4.
- c. Investigators, researchers and other relevant personnel must take account of the risks a study poses when designing research to be sponsored by Royal Papworth and take steps to minimise or avoid such risks
- d. The Clinical Project Manager assigned to the study or the Operational Research team and Research Governance Team (in the case of non-Royal Papworth Sponsored studies) is responsible for performing a risk assessment for that study, and the members of the Research Governance Project Approval System Committee (RGPAS) are responsible for

reviewing and agreeing the risk assessment. A draft / initial risk assessments should be included within the RGPAS document pack when an internally or externally sponsored study is presented to the RGPAS for review.

- e. The Clinical Project Manager (or member of the Operational Research Team and / Research Governance Team as appropriate) is responsible for notifying the Investigator of any identified risks and the generation and review of any associated action plans.
- f. Senior Managers within R&D are responsible for escalation of risks over 12 to the Trust Risk Register. All new risks are discussed at the Trust Risk Management Group (RMG) and approved where appropriate. Once discussed at RMG a risk of 15 and above may be escalated to the Board Assurance Framework (BAF).

3 Policy

- a. This SOP is mandatory and, as per the Trust's Information Governance and Records Management framework, non-compliance may result in disciplinary procedures.

4 Procedure

- a. All research taking place within the Trust must undergo formal risk assessment prior to TCCC and commencement of the research. The outcome of the risk assessment is Risk Rating Number (RRN), which determines how the risk is recorded and managed.
- b. All Studies: For all Royal Papworth sponsored research, management and mitigation of risk commences during the process of protocol writing, and is a continual review process in partnership with all stakeholders involved in the protocol development, and the leads for the relevant clinical directorate(s). Risks identified and actions to mitigate risks are recorded during protocol development. The risks identified are taken into consideration of the sponsorship of the study. See [SOP065 - Pragmatic Risk Assessment for Clinical Trials](#)
- c. Once the protocol has been finalised, the study must be presented to the RGPAS Committee (prior to submission of all study documentation to the appropriate authorities via the Integrated Research Application System (IRAS)). The Chief Investigator (CI) will be notified of any additional risks identified at this meeting, along with any actions that are required to be taken in order to mitigate risks identified.

- d. In the case of both Royal Papworth Sponsored and externally sponsored studies, a further review of the draft / initial risk assessment of the study will be confirmed prior to Trust confirmation, alongside obtaining Directorate Authorisations, by completing [FRM013: Risk Assessment Tool](#) in conjunction with the study team and by reviewing the IRAS form, Protocol, Patient Information Sheet (PIS) and Consent forms. Notification will be sent to the CI or PI as appropriate.
- e. Severity of risk should be graded by consideration of the potential for:
- Risk to the Participant
 - Risk to staff
 - Risk to the Study
 - Risk to the Trust
- f. Likelihood of risk in each area should be graded by assigning a predicted frequency of occurrence of the adverse outcome (1-insignificant to 5-Catastrophic). All risk assessments will be electronically signed by the operational team member and / or a Clinical Project Manager reviewing the risk assessment prior to the issuing of TCCC. Where risk assessments have an overall score of >15 the PI will be asked to countersign indicating their agreement to the risks and mitigations and to agree to the overall scoring.
- g. The form: Risk Assessment Tool describes in detail the issues for consideration in each of the three areas see [FRM013: Risk Assessment Tool](#). FRM013 is a guidance tool and provides some areas of consideration for risks. Risks not listed on the FRM013 can be added as relevant to the study under review. Risks listed can be moved to higher or low categories if relevant to the study under review. An outline of the risks, there mitigations and scoring both before and after mitigation, should be outlined within the narrative box at the end of the risk assessment. An overall risk scoring should be provided for before and after mitigation.

Table 1: Risk Matrix

- h. The risk for each category is assessed against likelihood. The RRN is calculated from the formula; $RRN = \text{severity} \times \text{likelihood}$ and is based on risk when all the identified controls are in place and operating. (See Table 1):

Risk to Participant For example..	Participant inconvenienced	Unexpected complications	Some permanent loss of function/ earnings National Press Prosecution	Major disability or death	Multiple disability or deaths
Risk to Study For example..	Competing trials	Slow recruitment, time target not met	Recruitment not met	No valid data or learning. Fraudulent data	Misrepresented findings impact on standard clinical practice
Risk to Trust For example..	Impact on service eg staffing	~1 day local press Financial loss <£5k	National Press Prosecution Financial loss <£100k	DoH action Financial loss < £5m	Major Inquiry Financial loss >£5m
	1 Insignificant	2 Minor	3 Moderate	4 Major	5 Catastrophic
Likelihood					
1 Rare	1	2	3	4	5
2 Unlikely	2	4	6	8	10
3 Possible	3	6	9	12	15
4 Likely	4	8	12	16	20
5 Almost	5	10	15	20	25

i. Possible likelihood parameters are outlined in Table 2 below:

Likelihood score	1	2	3	4	5
Descriptor	Rare	Unlikely	Possible	Likely	Almost Certain
Frequency. How often might it / does it happen	This will probably never happen / recur	Do not expect it to happen / recur but it is possible it may do so	Might happen or recur occasionally	Will probably happen / recur but it is not a persisting issue	Will undoubtedly happen / recur, possibly frequently
Time- framed descriptors	Not expected to occur for years	Expected to occur at least annually	Expected to occur at least monthly	Expected occur at least weekly	Expected to occur at least daily
Probability descriptors	<0.1 per cent	0.1- 1 percent	1 – 10 percent	10-50 percent	>50 percent

- j. The highest risk rating from the 3 areas determines the overall RRN. If the risk for a certain area can be reduced or controlled via measures, the risk can be re-assessed.
- k. If actions and/ or measures to mitigate risk are required these are recorded on the Risk Assessment Tool and shared with the CI or PI, with a copy retained by the Research Governance Team and in the TMF or site file as appropriate, with actions being reviewed and recorded.
- l. An overall risk assignment is given to the trial once unanimous agreement is reached by key stakeholders involved in the research. Risks that cannot be agreed upon will be escalated to the RGPAS panel for review and further escalation if required.
- m. The level of risk assigned to the study is reported and monitored in accordance with the Risk Assessment Procedure DN290 <https://staff.royalpapworth.nhs.uk/download.cfm?ver=9152> and Risk Management Strategy DN139 [DN139 - Risk Management Strategy \(royalpapworth.nhs.uk\)](#) , and consequent monitoring arrangements will be notified to the investigator.

5 Risk Management / Liability / Monitoring & Audit

- a. The R&D SOP Committee will ensure that this SOP and any future changes to this document are adequately disseminated.
- b. The R&D Department will monitor adherence to this SOP via the routine audit and monitoring of individual clinical trials and the Trust's auditors will monitor this SOP as part of their audit of Research Governance. From time to time, the SOP may also be inspected by external regulatory agencies (e.g. Care Quality Commission, Medicines and Healthcare Regulatory Agency).
- c. In exceptional circumstances it might be necessary to deviate from this SOP for which written approval of the Senior R&D Manager should be gained before any action is taken. SOP deviations should be recorded including details of alternative procedures followed and filed in the Investigator and Sponsor Master File.
- d. The Research and Development Directorate is responsible for the ratification of this procedure.

Further Document Information

Approved by: <i>Management/Clinical Directorate Group</i>	Research and Development Directorate						
Approval date: <i>(this version)</i>	Current active version approved date						
Ratified by Board of Directors/ Committee of the Board of Directors:	STET						
Date:	N/A						
This document supports: <i>Standards and legislation</i>	Medicines for Human Use (Clinical Trials) Regulations 2004 and all associated amendments. UK Policy Framework for Health and Social Care Research (2018)						
Key related documents:	Trust Research Policy DN139 Risk Management Strategy DN290 Risk Assessment Procedure Research and Development Standard Operating Procedures entitled: SOP016 Monitoring Research Studies SOP034 Trust Confirmation of Capacity and Capability to Conduct Research Studies SOP065 - Pragmatic Risk Assessment for Clinical Trials FRM013 Risk Assessment Tool						
Equality Impact Assessment: Does this document impact on any of the following groups? If YES, state positive or negative, complete Equality Impact Assessment Form available in Disability Equality Scheme document DN192 and attach.							
Groups	Disability	Race	Gender	Age	Sexual orientation	Religious & belief	Other
Yes/No	NO	NO	NO	NO	NO	NO	No
Positive/Negative							
Review date:	July 2025						

DocuSigned by:



81A52758BFFF421...

22-Sep-2023

Signed by Dr Patrick Calvert, Clinical Director of R&D

Date